Publication | Closed Access

Strong CD8+ T-cell responses against tumor-associated antigens prolong the recurrence-free interval after tumor treatment in patients with hepatocellular carcinoma

Cancer ImmunosurveillanceMedicineImmunologyImmune Checkpoint InhibitorCd4 T Cell ResponsesTumor TreatmentImmune Cell TherapyImmunotherapyOncologyRadiation OncologyTumor MicroenvironmentHepatocellular CarcinomaRecurrence-free Interval